Ozempic / GLP-1 Gastroparesis (Stomach Paralysis) Lawsuit

Ozempic gastroparesis (“stomach paralysis”) lawsuits: claimants allege that GLP-1 drugs — including Ozempic, Wegovy and Rybelsus (Novo Nordisk) and Mounjaro, Zepbound and Trulicity (Eli Lilly) — contributed to severe stomach and GI injuries such as gastroparesis, intestinal obstruction, pancreatitis and gallbladder disease, and that the makers failed to warn (per complaints and firm pages). Individual lawsuits are being filed in U.S. federal and state courts; as of September 2026 no consolidated MDL for the stomach-injury claims is on the public record, and the FDA has reviewed adverse-event reports and updated GLP-1 class labeling (per FDA and firm pages, Sep 2026). A related but separate MDL (3163, NAION/vision loss) covers optic-nerve claims. We track the public record — we do not promise or predict outcomes.

Status of the science / claims: Gastroparesis (delayed gastric emptying, “stomach paralysis”) is a gastrointestinal condition reported in adverse-event reports for GLP-1 receptor agonist use; the FDA has reviewed the class’s adverse-event reports and updated class labeling (per FDA). Causation in individual cases is contested; no controlling determination is on the public record as of this update.